TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trinity Biotech PLC (TRIB) is not a good buy at this moment for a beginner investor with a long-term strategy. The stock lacks strong positive catalysts, has no significant trading signals, and its financial performance remains stagnant with no growth in revenue or net income. Additionally, the technical indicators and options data do not suggest a compelling entry point.
The MACD is positive but contracting, RSI is neutral at 63.422, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 0.652, with resistance at 0.724 and support at 0.58. Pre-market price is down 2.52%, showing weakness.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Pre-market price decline of 2.52%. Financials show no YoY growth in revenue, net income, or EPS. Lack of recent congress trading data or influential figure activity.
In Q3 2024, revenue remained flat at $15,152,000 YoY, net income was negative at -$4,759,000, and EPS was -0.04. Gross margin was 35.44%, with no growth trends observed.
No recent analyst ratings or price target changes available.
